Literature DB >> 1423203

Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis.

N M Marina1, C B Pratt, B N Rao, S J Shema, W H Meyer.   

Abstract

BACKGROUND: A poor outcome is traditionally ascribed to osteosarcoma metastatic to the lungs, but data have been unavailable regarding the outcome of such patients after systematic treatment on clinical trials.
METHODS: The clinical course and outcome of 31 patients who had osteosarcoma metastatic to the lungs diagnosed between 1962 and 1990 at St. Jude Children's Research Hospital were reviewed to determine whether the use of increasingly aggressive multimodality therapy has improved their outcome. The patients were grouped by treatment eras, based on major changes in therapy (i.e., single-agent or two-agent era, 1962-1972; standard multiagent era, 1972-1982; and intensive multiagent era, 1982-1990).
RESULTS: With increasingly intensive chemotherapy, more aggressive efforts to resect metastatic disease, and earlier detection of pulmonary metastases by computed tomography, the survival of these patients has improved significantly over the 28-year study period. Those treated since 1982 have a 50% estimated probability of survival at 3 years, whereas there were no survivors at 3 years in the two earlier eras. Survival for the former group reached a plateau of 30% at 4 years.
CONCLUSIONS: The use of aggressive multimodality therapy, coupled with modern pediatric imaging techniques to detect pulmonary disease, has improved the traditionally dismal outlook in pediatric patients with osteosarcoma and synchronous pulmonary metastases.

Entities:  

Mesh:

Year:  1992        PMID: 1423203     DOI: 10.1002/1097-0142(19921201)70:11<2722::aid-cncr2820701125>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.

Authors:  V Nataraj; S Rastogi; S A Khan; M C Sharma; S Agarwala; S Vishnubhatla; S Bakhshi
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

2.  Unusual abdominal metastases in osteosarcoma.

Authors:  Simon Berhe; Enrico Danzer; Paul Meyers; Gerald Behr; Michael P LaQuaglia; Anita P Price
Journal:  J Pediatr Surg Case Rep       Date:  2018-01

Review 3.  The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.

Authors:  Xin Xiao; Wei Wang; Zhen Wang
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

4.  Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.

Authors:  Elyssa M Rubin; Yi Guo; Khoa Tu; Jun Xie; Xiaolin Zi; Bang H Hoang
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

5.  Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents.

Authors:  Cristina Meazza; Roberto Luksch; Primo Daolio; Marta Podda; Alessandro Luzzati; Alessandro Gronchi; Antonina Parafioriti; Lorenza Gandola; Paola Collini; Andrea Ferrari; Michela Casanova; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Veronica Biassoni; Elisabetta Schiavello; Emilia Pecori; Maura Massimino
Journal:  Med Oncol       Date:  2014-02-21       Impact factor: 3.064

6.  The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients.

Authors:  Yu-Min Huang; Chun-Han Hou; Sheng-Mou Hou; Rong-Sen Yang
Journal:  Clin Med Oncol       Date:  2009-09-14

7.  Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer center.

Authors:  Samer Salah; Rami Ahmad; Iyad Sultan; Sameer Yaser; Ahmad Shehadeh
Journal:  Mol Clin Oncol       Date:  2014-06-23

8.  Should contralateral exploratory thoracotomy be advocated for children with osteosarcoma and early unilateral pulmonary metastases?

Authors:  Gideon Karplus; M Beth McCarville; Matthew P Smeltzer; George Spyridis; Bhaskar N Rao; Andrew Davidoff; Chin-Shang Li; Stephen Shochat
Journal:  J Pediatr Surg       Date:  2009-04       Impact factor: 2.545

9.  Establishment and characterization of OS 99-1, a cell line derived from a highly aggressive primary human osteosarcoma.

Authors:  Jennifer M Gillette; C Parker Gibbs; Sheila M Nielsen-Preiss
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-02-05       Impact factor: 2.416

10.  A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.

Authors:  Michael S Isakoff; Robert Goldsby; Doojduen Villaluna; Mark D Krailo; Pooja Hingorani; Anderson Collier; Carol D Morris; E Anders Kolb; John J Doski; Richard B Womer; Richard Gorlick; Katherine A Janeway
Journal:  Pediatr Blood Cancer       Date:  2018-10-30       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.